Symptoms and Severity of COVID-19 in Patients with Immune-Mediated Inflammatory Diseases: Experience of a University Medical Center

Table 11

Systemic glucocorticoid therapy of IMID patients at the time of survey.

	With history of COVID-19^†		Without history of COVID-19^†		Chi^2	t test
	No.	%	No.	%
	81	100	72	100
Systemic glucocorticoid^‡	11	13.6	22	30.6	0.02
Dosage (mg)
Mean	10.5		10.3			0.98
Median	5		5
Range	1–60		2–50

IMID: immune-mediated inflammatory disease; COVID-19: coronavirus disease 2019; ; ^†data obtained by 153 patients; ^‡to facilitate calculations, all individual dosages were standardized by conversion to a prednisone equivalent [28].